Inogen, Inc. (NASDAQ:INGN) Stock Position Increased by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its position in Inogen, Inc. (NASDAQ:INGN) by 2.7% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 896,106 shares of the medical technology company’s stock after purchasing an additional 23,891 shares during the quarter. JPMorgan Chase & Co. owned about 3.76% of Inogen worth $8,692,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Franklin Resources Inc. bought a new stake in shares of Inogen during the 3rd quarter worth about $139,000. Virtu Financial LLC bought a new stake in shares of Inogen during the 3rd quarter worth about $111,000. Barclays PLC raised its position in shares of Inogen by 72.9% during the 3rd quarter. Barclays PLC now owns 55,508 shares of the medical technology company’s stock worth $539,000 after buying an additional 23,398 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Inogen by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 554,191 shares of the medical technology company’s stock worth $5,377,000 after buying an additional 5,921 shares in the last quarter. Finally, State Street Corp raised its position in shares of Inogen by 2.8% during the 3rd quarter. State Street Corp now owns 511,018 shares of the medical technology company’s stock worth $4,957,000 after buying an additional 14,054 shares in the last quarter. 89.94% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on INGN shares. Needham & Company LLC restated a “hold” rating on shares of Inogen in a research report on Friday, November 8th. StockNews.com downgraded shares of Inogen from a “buy” rating to a “hold” rating in a research report on Friday, December 20th.

Inogen Price Performance

Shares of INGN opened at $10.33 on Tuesday. The firm’s 50 day moving average is $9.46 and its 200-day moving average is $9.88. The stock has a market capitalization of $246.04 million, a P/E ratio of -4.59 and a beta of 1.02. Inogen, Inc. has a 12-month low of $5.08 and a 12-month high of $13.33.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.